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Dear Editor,  
Benzodiazepine (BZD) prescribing is common in Ireland1. Current guidelines recommend that 
prescriptions should be short term (< 4 weeks), yet long-term prescribing persists2. BZD misuse 
affects individuals, their families and society at large due to hospitalizations, substance dependence 
treatment and crime3. Despite having medical guidelines for appropriate prescribing, BZD 
management and withdrawal is, typically, poorly managed and has a reputation for being difficult for 
doctors and patients. Due to the Covid-19 pandemic health systems worldwide have had to adapt to 
meet varied health needs4. This study explores how Covid-19 has impacted medical professionals’ 
prescribing practices of BZD’s. 
In early 2020, medical professionals working in General Practice, Addiction Services, Emergency 
Departments and Psychiatric Settings, in the HSE South/Southwest region of Ireland were recruited 
by HSE Addictions Services South. Focus groups were conducted to capture how medical 
professionals manage individuals who use BZD’s in their practice and how Covid-19 has impacted 
upon their prescribing practices.  Ethical approval was granted by the UCC, School of Applied 
Psychology ethics committee. In total, 6 online focus groups (52 participants) were carried out 
between July and November 2020.  
Qualitative framework analysis surrounding the impact of Covid-19 identified three main themes: 
how telemedicine has sometimes reduced the pressure felt by medical professionals to prescribe 
benzodiazepines; the benefits of e-prescribing for prescription management; the effectiveness of the 
harm reduction approach that was implemented nationally due to Covid-19 restrictions. In relation 
to reduced pressure, one GP noted that: “you can issue your script without the person standing over 
you or them being in your presence so it allows a bit more time and…a little more headspace to start 
a good change”. Participants also identified some difficulties resulting from Covid-19, including the 
uncertainty of patient well-being due to phone consultations and non-attendance. The importance 
of continuous evaluation of Covid-19’s impact was evident across all 6 focus groups.  
 
From this study, it appears there have been some positive changes to medical practitioners’ 
prescribing practices, as a result of Covid-19. Thus, telemedicine, e-prescribing and harm reduction 
approach, have demonstrated some positive changes from the practitioners’ perspective. The 
outcome for patients, though, was not explored in this study and remains unclear. Future research 
would benefit from continuous evaluation of the impact of Covid-19 on medical practice and the 




School of Applied Psychology,  
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